← All trials
NCT05360953
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 6, 2022
- Primary completion
- Jul 31, 2024
- Completion date
- Apr 1, 2025
- First posted
- May 4, 2022
- Last posted
- May 4, 2022
- Enrollment
- 189
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humboldt UniversityLead sponsor
- Humboldt UniversityOverall official - principal investigator
- Humboldt UniversityReponsible party - principal investigator
- German Federal Ministry of Education and ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.